To include your compound in the COVID-19 Resource Center, submit it here.

Omega: Flagship’s latest venture into the chromatin white space

Omega’s launch deepens Flagship’s investment in chromatin structure-based gene control

Flagship’s latest foray into white space technologies, Omega Therapeutics, is the newest company to tackle gene control by intervening at the 3-D chromatin structure level.

With a platform that homes in on the structural elements surrounding individual or small groups of genes, the company may be able to selectively regulate gene expression across a broad swath of indications.

Founded in 2017 in Flagship Pioneering’s Flagship Labs incubator, Omega

Read the full 680 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers